You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
陽光諾和(688621.SH):目前利用固相合成技術已經可以穩定合成司美格魯肽、替爾泊肽等藥物
格隆匯 12-23 15:54

格隆匯12月23日丨陽光諾和(688621.SH)在投資者互動平台表示,我司全資子公司成都諾和晟泰生物科技有限公司,作為我司重點構建的多肽、類肽藥物創新研發平台,形成了獨具特色的多肽藥物創新開發模式。公司目前利用固相合成技術已經可以穩定合成司美格魯肽、替爾泊肽等藥物,可根據市場及公司業務佈局開展深入研究。目前,我司正在執行的GLP-1一類創新藥臨牀試驗服務共計6項,涵蓋減重及降糖適應症,分別處於臨牀I至III期研究階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account